Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD Source: Annual Congress 2006 - COPD therapy Year: 2006
Inhaled vilanterol trifenatate/fluticasone furoate (VFF) improves respiratory muscle function and walking performance in severe COPD without change in pulmonary function Source: International Congress 2017 – Management of COPD Year: 2017
Endurance shuttle walking test: responsiveness to salmeterol in COPD Source: Eur Respir J 2008; 31: 579-584 Year: 2008
Degree of exercise limitation in COPD: impact on 6 minute walk (6MW) in response to long-acting β-agonist (LABA) treatment Source: Eur Respir J 2007; 30: Suppl. 51, 76s Year: 2007
Improvements with tiotropium on endurance measured by the shuttle walking test (SWT) and on health related quality of life (HRQoL) in COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 287s Year: 2002
Clinical improvement with salmeterol/fluticasone propionate (SFC) is associated with reduction in inflammation in patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 717s Year: 2005
Effect of fluticasone propionate/salmeterol on exercise endurance in moderate-severe COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
The effects of adding formoterol (F) and tiotropium (T) on exercise performance and breathlessness in patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 577s Year: 2005
Superiority of the ‘triple‘ therapy of salmeterol/fluticasone propionate (SFC) and tiotropium (TIO) vs. individual components in COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Effect of 8 and 12 weeks’ once-daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with COPD Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD Source: Eur Respir J 2013; 42: 539-541 Year: 2013
Tiotropium improves walking endurance in COPD Source: Eur Respir J 2012; 39: 265-271 Year: 2012
Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Effects of inhaled formoterol on dynamic hyperinflation during and after incremental treadmill exercise in patients with advanced COPD Source: Eur Respir J 2006; 28: Suppl. 50, 172s Year: 2006
Relation between the acute response to salbutamol and long-term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T+F) in COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Comparison of the short-term effect of tiotropium (TIO) vs a combination therapy with single inhaler budesonide/formoterol (symbicort) on the degree of pulmonary hyperinflation Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004
Evaluation of hyperinflation parameters and exercise performance at maximal exercise in patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 63s Year: 2005
Differentiation of bronchodilator effects of indacaterol and formoterol by FEV1 and inspiratory capacity (IC) in patients with COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007